Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response
Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug conjugates (ADCs) into clinical trials. While three MMAE-ADCs have been approved, most of these conjugates are no longer being investigated in c...
Saved in:
| Published in | mAbs Vol. 13; no. 1; p. 1862452 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Taylor & Francis
01.01.2021
Taylor & Francis Group |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug conjugates (ADCs) into clinical trials. While three MMAE-ADCs have been approved, most of these conjugates are no longer being investigated in clinical trials. Some auristatin conjugates show limited or no efficacy at tolerated doses, but even for drugs driving initial remissions, tumor regrowth and metastasis often rapidly occur. Here we describe the development of second-generation therapeutic ADCs targeting Lymphocyte antigen 6E (Ly6E) where the tubulin polymerization inhibitor MMAE (Compound
) is replaced with DNA-damaging agents intended to drive increased durability of response. Comparison of a
-cyclopropyl benzoindol-4-one (CBI)-dimer (compound
) to MMAE showed increased potency, activity across more cell lines, and resistance to efflux by
-glycoprotein, a drug transporter commonly upregulated in tumors. Both anti-Ly6E-CBI and -MMAE conjugates drove single-dose efficacy in xenograft and patient-derived xenograft models, but
CBI-dimer conjugates showed reduced tumor outgrowth following multiple weeks of treatment, suggesting that they are less susceptible to developing resistance. In parallel, we explored approaches to optimize the targeting antibody. In contrast to immunization with recombinant Ly6E or Ly6E DNA, immunization with virus-like particles generated a high-affinity anti-Ly6E antibody. Conjugates to this antibody improve efficacy versus a previous clinical candidate both
and
with multiple cytotoxics. Conjugation of compound
to the second-generation antibody results in a substantially improved ADC with promising preclinical efficacy. |
|---|---|
| AbstractList | Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug conjugates (ADCs) into clinical trials. While three MMAE-ADCs have been approved, most of these conjugates are no longer being investigated in clinical trials. Some auristatin conjugates show limited or no efficacy at tolerated doses, but even for drugs driving initial remissions, tumor regrowth and metastasis often rapidly occur. Here we describe the development of second-generation therapeutic ADCs targeting Lymphocyte antigen 6E (Ly6E) where the tubulin polymerization inhibitor MMAE (Compound
) is replaced with DNA-damaging agents intended to drive increased durability of response. Comparison of a
-cyclopropyl benzoindol-4-one (CBI)-dimer (compound
) to MMAE showed increased potency, activity across more cell lines, and resistance to efflux by
-glycoprotein, a drug transporter commonly upregulated in tumors. Both anti-Ly6E-CBI and -MMAE conjugates drove single-dose efficacy in xenograft and patient-derived xenograft models, but
CBI-dimer conjugates showed reduced tumor outgrowth following multiple weeks of treatment, suggesting that they are less susceptible to developing resistance. In parallel, we explored approaches to optimize the targeting antibody. In contrast to immunization with recombinant Ly6E or Ly6E DNA, immunization with virus-like particles generated a high-affinity anti-Ly6E antibody. Conjugates to this antibody improve efficacy versus a previous clinical candidate both
and
with multiple cytotoxics. Conjugation of compound
to the second-generation antibody results in a substantially improved ADC with promising preclinical efficacy. Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug conjugates (ADCs) into clinical trials. While three MMAE-ADCs have been approved, most of these conjugates are no longer being investigated in clinical trials. Some auristatin conjugates show limited or no efficacy at tolerated doses, but even for drugs driving initial remissions, tumor regrowth and metastasis often rapidly occur. Here we describe the development of second-generation therapeutic ADCs targeting Lymphocyte antigen 6E (Ly6E) where the tubulin polymerization inhibitor MMAE (Compound 1 ) is replaced with DNA-damaging agents intended to drive increased durability of response. Comparison of a seco -cyclopropyl benzoindol-4-one (CBI)-dimer (compound 2 ) to MMAE showed increased potency, activity across more cell lines, and resistance to efflux by P -glycoprotein, a drug transporter commonly upregulated in tumors. Both anti-Ly6E-CBI and -MMAE conjugates drove single-dose efficacy in xenograft and patient-derived xenograft models, but seco- CBI-dimer conjugates showed reduced tumor outgrowth following multiple weeks of treatment, suggesting that they are less susceptible to developing resistance. In parallel, we explored approaches to optimize the targeting antibody. In contrast to immunization with recombinant Ly6E or Ly6E DNA, immunization with virus-like particles generated a high-affinity anti-Ly6E antibody. Conjugates to this antibody improve efficacy versus a previous clinical candidate both in vitro and in vivo with multiple cytotoxics. Conjugation of compound 2 to the second-generation antibody results in a substantially improved ADC with promising preclinical efficacy. Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug conjugates (ADCs) into clinical trials. While three MMAE-ADCs have been approved, most of these conjugates are no longer being investigated in clinical trials. Some auristatin conjugates show limited or no efficacy at tolerated doses, but even for drugs driving initial remissions, tumor regrowth and metastasis often rapidly occur. Here we describe the development of second-generation therapeutic ADCs targeting Lymphocyte antigen 6E (Ly6E) where the tubulin polymerization inhibitor MMAE (Compound 1) is replaced with DNA-damaging agents intended to drive increased durability of response. Comparison of a seco-cyclopropyl benzoindol-4-one (CBI)-dimer (compound 2) to MMAE showed increased potency, activity across more cell lines, and resistance to efflux by P-glycoprotein, a drug transporter commonly upregulated in tumors. Both anti-Ly6E-CBI and -MMAE conjugates drove single-dose efficacy in xenograft and patient-derived xenograft models, but seco-CBI-dimer conjugates showed reduced tumor outgrowth following multiple weeks of treatment, suggesting that they are less susceptible to developing resistance. In parallel, we explored approaches to optimize the targeting antibody. In contrast to immunization with recombinant Ly6E or Ly6E DNA, immunization with virus-like particles generated a high-affinity anti-Ly6E antibody. Conjugates to this antibody improve efficacy versus a previous clinical candidate both in vitro and in vivo with multiple cytotoxics. Conjugation of compound 2 to the second-generation antibody results in a substantially improved ADC with promising preclinical efficacy.Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug conjugates (ADCs) into clinical trials. While three MMAE-ADCs have been approved, most of these conjugates are no longer being investigated in clinical trials. Some auristatin conjugates show limited or no efficacy at tolerated doses, but even for drugs driving initial remissions, tumor regrowth and metastasis often rapidly occur. Here we describe the development of second-generation therapeutic ADCs targeting Lymphocyte antigen 6E (Ly6E) where the tubulin polymerization inhibitor MMAE (Compound 1) is replaced with DNA-damaging agents intended to drive increased durability of response. Comparison of a seco-cyclopropyl benzoindol-4-one (CBI)-dimer (compound 2) to MMAE showed increased potency, activity across more cell lines, and resistance to efflux by P-glycoprotein, a drug transporter commonly upregulated in tumors. Both anti-Ly6E-CBI and -MMAE conjugates drove single-dose efficacy in xenograft and patient-derived xenograft models, but seco-CBI-dimer conjugates showed reduced tumor outgrowth following multiple weeks of treatment, suggesting that they are less susceptible to developing resistance. In parallel, we explored approaches to optimize the targeting antibody. In contrast to immunization with recombinant Ly6E or Ly6E DNA, immunization with virus-like particles generated a high-affinity anti-Ly6E antibody. Conjugates to this antibody improve efficacy versus a previous clinical candidate both in vitro and in vivo with multiple cytotoxics. Conjugation of compound 2 to the second-generation antibody results in a substantially improved ADC with promising preclinical efficacy. Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug conjugates (ADCs) into clinical trials. While three MMAE-ADCs have been approved, most of these conjugates are no longer being investigated in clinical trials. Some auristatin conjugates show limited or no efficacy at tolerated doses, but even for drugs driving initial remissions, tumor regrowth and metastasis often rapidly occur. Here we describe the development of second-generation therapeutic ADCs targeting Lymphocyte antigen 6E (Ly6E) where the tubulin polymerization inhibitor MMAE (Compound 1) is replaced with DNA-damaging agents intended to drive increased durability of response. Comparison of a seco-cyclopropyl benzoindol-4-one (CBI)-dimer (compound 2) to MMAE showed increased potency, activity across more cell lines, and resistance to efflux by P-glycoprotein, a drug transporter commonly upregulated in tumors. Both anti-Ly6E-CBI and -MMAE conjugates drove single-dose efficacy in xenograft and patient-derived xenograft models, but seco-CBI-dimer conjugates showed reduced tumor outgrowth following multiple weeks of treatment, suggesting that they are less susceptible to developing resistance. In parallel, we explored approaches to optimize the targeting antibody. In contrast to immunization with recombinant Ly6E or Ly6E DNA, immunization with virus-like particles generated a high-affinity anti-Ly6E antibody. Conjugates to this antibody improve efficacy versus a previous clinical candidate both in vitro and in vivo with multiple cytotoxics. Conjugation of compound 2 to the second-generation antibody results in a substantially improved ADC with promising preclinical efficacy. |
| Author | Dragovich, Peter S. Boswell, C. Andrew Agard, Nicholas J. Go, MaryAnn Rowntree, Rebecca K Zhang, Pamela Mandikian, Danielle Sadowsky, Jack Chen, Yvonne Kozak, Katherine R. Sharpnack, Danielle Polson, Andrew G. Phillips, Gail D. Dela Cruz Chuh, Josefa Yu, Shang-Fan Seshasayee, Dhaya Chan, Pamela Lin, Zhonghua Vij, Rajesh Sun, Yonglian Schneider, Kellen Polakis, Paul Pillow, Thomas H. Koerber, James T. Guo, Jun de la Cruz, Cecile Rafidi, Hanine |
| Author_xml | – sequence: 1 givenname: Josefa surname: Dela Cruz Chuh fullname: Dela Cruz Chuh, Josefa organization: Departments of Biochemical and Cellular Pharmacology, Genentech Inc, South San Francisco, CA, USA – sequence: 2 givenname: MaryAnn surname: Go fullname: Go, MaryAnn organization: Research biology, Genentech Inc, South San Francisco, CA, USA – sequence: 3 givenname: Yvonne surname: Chen fullname: Chen, Yvonne organization: Antibody Engineering, Genentech Inc, South San Francisco, CA, USA – sequence: 4 givenname: Jun surname: Guo fullname: Guo, Jun organization: Research biology, Genentech Inc, South San Francisco, CA, USA – sequence: 5 givenname: Hanine surname: Rafidi fullname: Rafidi, Hanine organization: Preclinical & Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc, South San Francisco, CA, USA – sequence: 6 givenname: Danielle surname: Mandikian fullname: Mandikian, Danielle organization: Preclinical & Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc, South San Francisco, CA, USA – sequence: 7 givenname: Yonglian surname: Sun fullname: Sun, Yonglian organization: Antibody Engineering, Genentech Inc, South San Francisco, CA, USA – sequence: 8 givenname: Zhonghua surname: Lin fullname: Lin, Zhonghua organization: Antibody Engineering, Genentech Inc, South San Francisco, CA, USA – sequence: 9 givenname: Kellen surname: Schneider fullname: Schneider, Kellen organization: Antibody Engineering, Genentech Inc, South San Francisco, CA, USA – sequence: 10 givenname: Pamela surname: Zhang fullname: Zhang, Pamela organization: Antibody Engineering, Genentech Inc, South San Francisco, CA, USA – sequence: 11 givenname: Rajesh surname: Vij fullname: Vij, Rajesh organization: Antibody Engineering, Genentech Inc, South San Francisco, CA, USA – sequence: 12 givenname: Danielle surname: Sharpnack fullname: Sharpnack, Danielle organization: Departments of Biochemical and Cellular Pharmacology, Genentech Inc, South San Francisco, CA, USA – sequence: 13 givenname: Pamela surname: Chan fullname: Chan, Pamela organization: Departments of Biochemical and Cellular Pharmacology, Genentech Inc, South San Francisco, CA, USA – sequence: 14 givenname: Cecile surname: de la Cruz fullname: de la Cruz, Cecile organization: Research biology, Genentech Inc, South San Francisco, CA, USA – sequence: 15 givenname: Jack surname: Sadowsky fullname: Sadowsky, Jack organization: Protein Chemistry, Genentech Inc, South San Francisco, CA, USA – sequence: 16 givenname: Dhaya surname: Seshasayee fullname: Seshasayee, Dhaya organization: Antibody Engineering, Genentech Inc, South San Francisco, CA, USA – sequence: 17 givenname: James T. surname: Koerber fullname: Koerber, James T. organization: Antibody Engineering, Genentech Inc, South San Francisco, CA, USA – sequence: 18 givenname: Thomas H. orcidid: 0000-0001-7300-1002 surname: Pillow fullname: Pillow, Thomas H. organization: Discovery Chemistry, Genentech Inc, South San Francisco, CA, USA – sequence: 19 givenname: Gail D. surname: Phillips fullname: Phillips, Gail D. organization: Research biology, Genentech Inc, South San Francisco, CA, USA – sequence: 20 givenname: Rebecca K surname: Rowntree fullname: Rowntree, Rebecca K organization: Research biology, Genentech Inc, South San Francisco, CA, USA – sequence: 21 givenname: C. Andrew surname: Boswell fullname: Boswell, C. Andrew organization: Preclinical & Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc, South San Francisco, CA, USA – sequence: 22 givenname: Katherine R. surname: Kozak fullname: Kozak, Katherine R. organization: Departments of Biochemical and Cellular Pharmacology, Genentech Inc, South San Francisco, CA, USA – sequence: 23 givenname: Andrew G. surname: Polson fullname: Polson, Andrew G. organization: Research biology, Genentech Inc, South San Francisco, CA, USA – sequence: 24 givenname: Paul surname: Polakis fullname: Polakis, Paul organization: Research biology, Genentech Inc, South San Francisco, CA, USA – sequence: 25 givenname: Shang-Fan surname: Yu fullname: Yu, Shang-Fan organization: Research biology, Genentech Inc, South San Francisco, CA, USA – sequence: 26 givenname: Peter S. surname: Dragovich fullname: Dragovich, Peter S. organization: Discovery Chemistry, Genentech Inc, South San Francisco, CA, USA – sequence: 27 givenname: Nicholas J. surname: Agard fullname: Agard, Nicholas J. organization: Antibody Engineering, Genentech Inc, South San Francisco, CA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33382956$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk9v1DAQxSNUREvpRwDlyCXFdvwvQkKqltJWWgkOvVuOPVlcEnuxHaTl0-N0tyvKBV88en7zG0vzXlcnPnioqrcYXWIk0QfcUYIkJ5cEkSKVijLyojpb9AZJgU6ONSen1UVKD2g5AmGBXlWnbdtK0jF-Vv34FsGMzjujxzpss5vcb51d8HUY6vWOXzdZxw1ksPXV51WqhxBr500EnYpk56h7N7q8q7W3NQxD4Zjd0qt9dk2ep-KPkLbBJ3hTvRz0mODicJ9X91-u71e3zfrrzd3qat0YKkRuetNqjS3nfc8AIWoxsJ53psctFYZJa4iVHWtpx6CzsuUW-pZ0i6s3hrTn1d0ea4N-UNvoJh13KminHoUQN0rH7MwIijAwlNsBdbKnlLMOD4KJwVJOBLItFNanPWs79xNYAz5HPT6DPn_x7rvahF9KCEmFlAXw_gCI4ecMKavJJQPjqD2EOSlCBWUIMy6K9d3fs45DnpZVDGxvMDGkFGE4WjBSSy7UUy7Ukgt1yEXp-_hPn3H5ccnly278T_cfViS9xg |
| CitedBy_id | crossref_primary_10_1093_carcin_bgac003 crossref_primary_10_3389_fonc_2022_929012 crossref_primary_10_1021_jacs_4c03529 crossref_primary_10_1155_2022_5164265 crossref_primary_10_1016_j_xphs_2023_07_005 crossref_primary_10_1111_bph_16258 crossref_primary_10_1016_j_jid_2022_07_022 crossref_primary_10_1007_s00262_024_03851_x crossref_primary_10_1080_19420862_2022_2115213 crossref_primary_10_2174_1871520623666221031105432 crossref_primary_10_1021_acs_oprd_2c00129 crossref_primary_10_3390_ijms23179843 |
| Cites_doi | 10.1093/ajhp/zxaa018 10.1182/blood-2006-09-047399 10.1182/blood-2009-02-205500 10.1124/dmd.120.000145 10.1038/nbt.1480 10.1038/s41598-018-25609-z 10.1111/cup.13545 10.1073/pnas.261563198 10.1038/s41598-018-28533-4 10.1093/annonc/mdw368.01 10.1038/nrclinonc.2010.228 10.1002/0471143030.cb0322s30 10.1158/1538-7445/AM2016-1207 10.1634/theoncologist.2015-0276 10.1200/JCO.2018.36.15_suppl.1014 10.1200/JCO.19.01140 10.1158/1541-7786.MCR-19-0582 10.1182/blood.V116.21.283.283 10.1021/acs.bioconjchem.9b00133 10.1158/1535-7163.MCT-16-0233 10.1126/scitranslmed.aat5775 10.1007/978-1-4939-9929-3_4 10.1038/srep21925 10.1016/S2352-3026(19)30026-2 10.3324/haematol.2018.211011 10.1002/sim.6052 10.3390/v11111020 10.1111/j.1365-2141.2009.07701.x 10.1158/1078-0432.CCR-15-0156 10.1038/356152a0 10.1159/000487453 10.1158/1078-0432.CCR-19-1133 10.2967/jnumed.106.037069 10.1002/9780471729259.mc1803s31 10.6004/jadpro.2018.9.6.9 10.1016/S0001-2998(05)80178-3 10.17265/2159-5313/2016.09.003 10.1158/0008-5472.CAN-17-3671 10.1158/0008-5472.CAN-10-2277 10.1073/pnas.63.1.78 10.1158/1078-0432.CCR-14-0012 10.1080/02648725.2013.801235 10.1007/s00280-015-2909-2 10.1080/19420862.2020.1715705 10.1038/s41598-018-22040-2 10.1134/S0026893319030154 10.1124/pr.114.009373 10.1111/cup.12797 10.1158/1078-0432.CCR-20-1067 10.1093/jnci/djv222 10.3390/cancers11030394 10.3389/fphar.2019.00749 10.1038/nbt832 10.1200/JCO.2016.70.8297 10.1016/j.jim.2009.01.005 10.4161/mabs.22189 |
| ContentType | Journal Article |
| Copyright | 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. 2020 The Author(s) |
| Copyright_xml | – notice: 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. 2020 The Author(s) |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1080/19420862.2020.1862452 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | J. DELA CRUZ CHUH ET AL |
| EISSN | 1942-0870 |
| ExternalDocumentID | oai_doaj_org_article_25ec46df098b446591f757fd46270d3e PMC7784788 33382956 10_1080_19420862_2020_1862452 |
| Genre | Journal Article |
| GroupedDBID | --- 00X 0YH 53G AAYXX ABCCY ABFIM ABPEM ACGFS ACTIO ADBBV ADCVX AEISY AENEX AIJEM AIYEW ALMA_UNASSIGNED_HOLDINGS AOIJS AQRUH BABNJ BAWUL BLEHA CCCUG CITATION DGEBU DIK DKSSO E3Z EBS EMOBN F5P GROUPED_DOAJ H13 HYE KTTOD KYCEM LJTGL M4Z O9- OK1 RPM SV3 TDBHL TFL TFW TR2 4.4 C1A CGR CUY CVF ECM EIF EJD NPM OVD TEORI TTHFI 7X8 5PM |
| ID | FETCH-LOGICAL-c477t-bc3aa1d66bb5e004d1e5b69cb1347c58dc2d8953495e9d836deb3291e5bbcc23 |
| IEDL.DBID | DOA |
| ISSN | 1942-0862 1942-0870 |
| IngestDate | Wed Aug 27 01:16:16 EDT 2025 Thu Aug 21 18:18:25 EDT 2025 Fri Jul 11 05:39:10 EDT 2025 Thu Apr 03 07:06:49 EDT 2025 Thu Apr 24 22:55:23 EDT 2025 Tue Jul 01 02:37:46 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | ADC resistance Ly6E virus-like particles antibody discovery Antibody-drug conjugate |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c477t-bc3aa1d66bb5e004d1e5b69cb1347c58dc2d8953495e9d836deb3291e5bbcc23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work |
| ORCID | 0000-0001-7300-1002 |
| OpenAccessLink | https://doaj.org/article/25ec46df098b446591f757fd46270d3e |
| PMID | 33382956 |
| PQID | 2474501567 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_25ec46df098b446591f757fd46270d3e pubmedcentral_primary_oai_pubmedcentral_nih_gov_7784788 proquest_miscellaneous_2474501567 pubmed_primary_33382956 crossref_primary_10_1080_19420862_2020_1862452 crossref_citationtrail_10_1080_19420862_2020_1862452 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-01 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | mAbs |
| PublicationTitleAlternate | MAbs |
| PublicationYear | 2021 |
| Publisher | Taylor & Francis Taylor & Francis Group |
| Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
| References | cit0033 cit0034 cit0031 cit0032 Gravanis I (cit0028) 2015; 21 cit0030 cit0039 cit0037 cit0038 cit0035 cit0036 cit0022 cit0023 cit0020 cit0029 cit0026 cit0027 cit0024 cit0025 cit0011 cit0055 cit0012 cit0056 cit0053 cit0010 cit0054 cit0051 cit0052 cit0050 cit0019 cit0017 cit0018 cit0015 cit0016 cit0013 cit0057 cit0014 cit0044 cit0001 cit0045 Wesolowska O (cit0021) 2005; 25 cit0042 cit0043 cit0040 cit0041 cit0008 cit0009 cit0006 cit0007 cit0004 cit0048 cit0005 cit0049 cit0002 cit0046 cit0003 cit0047 |
| References_xml | – ident: cit0031 doi: 10.1093/ajhp/zxaa018 – ident: cit0032 doi: 10.1182/blood-2006-09-047399 – volume: 25 start-page: 383 year: 2005 ident: cit0021 publication-title: Anticancer Res – ident: cit0012 doi: 10.1182/blood-2009-02-205500 – ident: cit0023 doi: 10.1124/dmd.120.000145 – ident: cit0022 doi: 10.1038/nbt.1480 – ident: cit0053 doi: 10.1038/s41598-018-25609-z – ident: cit0035 doi: 10.1111/cup.13545 – ident: cit0048 doi: 10.1073/pnas.261563198 – ident: cit0018 doi: 10.1038/s41598-018-28533-4 – ident: cit0006 doi: 10.1093/annonc/mdw368.01 – ident: cit0011 doi: 10.1038/nrclinonc.2010.228 – ident: cit0049 doi: 10.1002/0471143030.cb0322s30 – ident: cit0020 doi: 10.1158/1538-7445/AM2016-1207 – volume: 21 start-page: 102 year: 2015 ident: cit0028 publication-title: Oncol doi: 10.1634/theoncologist.2015-0276 – ident: cit0037 doi: 10.1200/JCO.2018.36.15_suppl.1014 – ident: cit0039 doi: 10.1200/JCO.19.01140 – ident: cit0027 doi: 10.1158/1541-7786.MCR-19-0582 – ident: cit0038 doi: 10.1182/blood.V116.21.283.283 – ident: cit0019 doi: 10.1021/acs.bioconjchem.9b00133 – ident: cit0017 doi: 10.1158/1535-7163.MCT-16-0233 – ident: cit0024 doi: 10.1126/scitranslmed.aat5775 – ident: cit0055 doi: 10.1007/978-1-4939-9929-3_4 – ident: cit0051 doi: 10.1038/srep21925 – ident: cit0040 doi: 10.1016/S2352-3026(19)30026-2 – ident: cit0042 doi: 10.3324/haematol.2018.211011 – ident: cit0057 doi: 10.1002/sim.6052 – ident: cit0003 doi: 10.3390/v11111020 – ident: cit0033 doi: 10.1111/j.1365-2141.2009.07701.x – ident: cit0001 doi: 10.1158/1078-0432.CCR-15-0156 – ident: cit0050 doi: 10.1038/356152a0 – ident: cit0004 doi: 10.1159/000487453 – ident: cit0041 doi: 10.1158/1078-0432.CCR-19-1133 – ident: cit0044 doi: 10.2967/jnumed.106.037069 – ident: cit0009 doi: 10.1002/9780471729259.mc1803s31 – ident: cit0030 doi: 10.6004/jadpro.2018.9.6.9 – ident: cit0026 doi: 10.1016/S0001-2998(05)80178-3 – ident: cit0005 doi: 10.17265/2159-5313/2016.09.003 – ident: cit0014 doi: 10.1158/0008-5472.CAN-17-3671 – ident: cit0045 doi: 10.1158/0008-5472.CAN-10-2277 – ident: cit0046 doi: 10.1073/pnas.63.1.78 – ident: cit0029 doi: 10.1158/1078-0432.CCR-14-0012 – ident: cit0047 doi: 10.1080/02648725.2013.801235 – ident: cit0036 doi: 10.1007/s00280-015-2909-2 – ident: cit0056 doi: 10.1080/19420862.2020.1715705 – ident: cit0002 doi: 10.1038/s41598-018-22040-2 – ident: cit0010 doi: 10.1134/S0026893319030154 – ident: cit0008 doi: 10.1124/pr.114.009373 – ident: cit0034 doi: 10.1111/cup.12797 – ident: cit0007 doi: 10.1158/1078-0432.CCR-20-1067 – ident: cit0016 doi: 10.1093/jnci/djv222 – ident: cit0013 doi: 10.3390/cancers11030394 – ident: cit0015 doi: 10.3389/fphar.2019.00749 – ident: cit0054 doi: 10.1038/nbt832 – ident: cit0043 doi: 10.1200/JCO.2016.70.8297 – ident: cit0052 doi: 10.1016/j.jim.2009.01.005 – ident: cit0025 doi: 10.4161/mabs.22189 |
| SSID | ssj0000070170 |
| Score | 2.33924 |
| Snippet | Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1862452 |
| SubjectTerms | ADC resistance Animals Antibodies, Monoclonal - immunology Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - pharmacology antibody discovery Antibody-drug conjugate Antigens, Surface - immunology Antineoplastic Agents - immunology Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - pharmacology Antineoplastic Agents, Immunological - pharmacokinetics Antineoplastic Agents, Immunological - pharmacology Cell Line, Tumor Cell Survival - drug effects Cell Survival - immunology Female GPI-Linked Proteins - immunology HEK293 Cells Humans Immunoconjugates - immunology Immunoconjugates - pharmacokinetics Immunoconjugates - pharmacology Ly6E Mice Mice, SCID Oligopeptides - immunology Rats Rats, Sprague-Dawley Tumor Burden - drug effects Tumor Burden - immunology virus-like particles Xenograft Model Antitumor Assays - methods |
| Title | Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33382956 https://www.proquest.com/docview/2474501567 https://pubmed.ncbi.nlm.nih.gov/PMC7784788 https://doaj.org/article/25ec46df098b446591f757fd46270d3e |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagJy6I8gyPykiop4Ym42eOpbRaIUB7WKRyiuJHxKo0i_Zx2H_fmTi73UVIvXCd2LLlGdsz8XzfMPahEL4tWhFz6zBWlTpWuWsE5A5MkE0JEBVhh79916Mf8suVutop9UU5YYkeOC3cKajopQ5tUVlH5F5V2Rpl2iA1mCKISKcv3nk7wVRyfA0Rw_RPyhJy8ts38B1bnJKMRBgeAooII6Fg72Lq-fv_5XT-nTu5cxldPmGPBy-Sn6XZH7IHsXvKjseJhnp9wid3qKrFCT_m4zuC6vUzdj3GY25ARPIZnhk3AxiTz1r-da0v8pQfHgM_-3y-4OjX8mlH7uUCRWE1T9zea950gUfioMBBqS9qaZovVzfYfp5yb-NzNrm8mJyP8qHoQu6lMcvcedE0ZdDaORVxB4UyKqcr7whz6pUNHoKtlMDAKlbBCh0wHIeKWjnvQbxgB92si68Yr2wDAVooomiktsZpb2n5PXhvXKEzJjcLXvuBkJzqYvyuy4G3dKOnmvRUD3rK2Mdttz-JkeO-Dp9Im9vGRKjdC9DM6sHM6vvMLGPvN7ZQ4wakV5Wmi7PVogZppCJAusnYy2Qb26GEEBYwAs2Y2bOavbnsf-mmv3qSb2MsVTZ4_T8m_4Y9AkrF6f8cvWUHy_kqvkNfaumO2MPi5-io3zy3encY4A |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preclinical+optimization+of+Ly6E-targeted+ADCs+for+increased+durability+and+efficacy+of+anti-tumor+response&rft.jtitle=mAbs&rft.au=Dela+Cruz+Chuh%2C+Josefa&rft.au=Go%2C+MaryAnn&rft.au=Chen%2C+Yvonne&rft.au=Guo%2C+Jun&rft.date=2021-01-01&rft.issn=1942-0870&rft.eissn=1942-0870&rft.volume=13&rft.issue=1&rft.spage=1862452&rft_id=info:doi/10.1080%2F19420862.2020.1862452&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1942-0862&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1942-0862&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1942-0862&client=summon |